Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a physician in the Taussig Cancer Institute at the Cleveland Clinic. His clinical and research interest is prostate cancer. He is a professor at the Cleveland Clinic Lerner College of Medicine and at the Case School of Medicine and is editor-in-chief for Urology (one of four major urologic journals). He has published more that 500 peer-reviewed papers including discovery papers that served as the basis for clinical assays for prostate cancer including isoPSA TM (a blood based assay with improved diagnostic accuracy) and OncotypeDx Prostate, a gene expression assay that characterizes biologic aggressiveness. He has helped establish a new histologic grading system for prostate cancer and is an advocate for the use of genomic testing in the treatment and surveillance of cancer.